WO2019180706A1 – September 26, 2019 – METHODS AND COMPOSITIONS FOR TREATING EPILEPSY AND ASSOCIATED DISORDERS

Please complete the required fields.




Inventors :

GEDO, Tamir - c/o Revadim Industrial Zone, 7982000 Revadim

Owner :

BOL PHARMA LTD.

Application Number :

WOIL19050301

Document Number :

WO2019180706A1

Priority Date :

March 19, 2018

Filing Date :

March 19, 2019

Date of Grant/ Publication :

September 26, 2019

Class :

A61K31 / 352

Abstract

The present invention provides cannabinoid combinations comprising, as the only cannabinoids, cannabidiol (CBD), cannabidivarin (CBDV), and optionally ? 9 -tetrahydrocannabinol (? 9 -THC), or an enantiomer, diastereomer, or racemate thereof, wherein the CBD and CBDV are at a weight ratio of from about 10: 1 to about 20: 1, and the CBD and ? 9 -THC, when present, are at a weight ratio of from about 20: 1 to about 30: 1; pharmaceutical and nutraceutical compositions comprising the cannabinoid combination; and methods for treating epilepsy or a disorder associated therewith, or for improving the efficacy of an anti-epileptic treatment, by administering said cannabinoid combinations.

Claim(s)

1. A method for treating epilepsy or a disorder associated therewith comprising administering to a subject in need thereof a therapeutically effective amount of a cannabinoid combination comprising, as the only cannabinoids, cannabidiol (CBD), cannabidivarin (CBDV), and optionally A 9 -tetrahydrocannabinol (A 9 -THC), or an enantiomer, diastereomer, or racemate thereof, wherein the CBD and CBDV are at a weight ratio of from about 10:1 to about 20:1, and the CBD and A 9 -THC, when present, are at a weight ratio of from about 20:1 to about 30:1.;
23. A method for improving the efficacy of an anti-epileptic treatment in a subject suffering from epilepsy or a disorder associated therewith and administered with an anti-epileptic drug (AED), said method comprising further administering to said subject a therapeutically effective amount of a cannabinoid combination comprising, as the only cannabinoids, cannabidiol (CBD), cannabidivarin (CBDV), and optionally A 9 -tetrahydrocannabinol (A 9 -THC), or an enantiomer, diastereomer, or racemate thereof, wherein the CBD and CBDV are at a weight ratio of from about 10:1 to about 20:1, and the CBD and A 9 -THC, when present, are at weight ratio of from about 20:1 to about 30:1.;
24. A cannabinoid combination comprising, as the only cannabinoids, cannabidiol (CBD), cannabidivarin (CBDV), and optionally A 9 -tetrahydrocannabinol (A 9 -THC), or an enantiomer, diastereomer, or racemate thereof, for use in treating epilepsy or a disorder associated therewith, wherein the CBD and CBDV are at a weight ratio of from about 10:1 to about 20:1, and the CBD and A 9 -THC, when present, are at weight ratio of from about 20:1 to about 30:1.;
32. A cannabinoid combination for use in improving the efficacy of an anti-epileptic treatment in a subject suffering from epilepsy or a disorder associated therewith and administered with an anti-epileptic drug (AED), said cannabinoid combination comprising, as the only cannabinoids, cannabidiol (CBD), cannabidivarin (CBDV), and optionally A 9 -tetrahydrocannabinol (A 9 -THC), or an enantiomer, diastereomer, or racemate thereof, wherein the CBD and CBDV are at a weight ratio of from about 10:1 to about 20:1, respectively, and the CBD and A 9 -THC, when present, are at weight ratio of from about 20:1 to about 30:1.;
34. A kit for use in treating epilepsy or a disorder associated therewith, comprising two or three composition, each composition comprising one or two of cannabidiol (CBD), cannabidivarin (CBDV), and A 9 -tetrahydrocannabinol (A 9 -THC), or an enantiomer, diastereomer, or racemate thereof, wherein the kit includes, as the only cannabinoids, CBD and CBDV, or CBD, CBDV, and A 9 -THC, and the CBD and CBDV in the kit are at a weight ratio of from about 10:1 to about 20:1, and the CBD and A 9 -THC, when present, in the kit are at weight ratio of from about 20:1 to about 30:1.;
35. A kit for use in improving the efficacy of an anti-epileptic treatment in a subject suffering from epilepsy or a disorder associated therewith and administered with an anti-epileptic drug (AED), comprising two or three composition, each composition comprising one or two of cannabidiol (CBD), cannabidivarin (CBDV), and A 9 -tetrahydrocannabinol (A 9 -THC), or an enantiomer, diastereomer, or racemate thereof, wherein the kit includes, as the only cannabinoids, CBD and CBDV, or CBD, CBDV, and A 9 -THC, and the CBD and CBDV in the kit are at a weight ratio of from about 20:1 to about 10:1, and the CBD and A 9 -THC, when present, in the kit are at weight ratio of from about 30:1 to about 20:1.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login